Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 50 of 70

    1.

    Economics and attitudes regarding spectacles in daily life: a European perspective.

    Lafuma A, Laurendeau C, Lamerain E, Berdeaux G.

    Ophthalmic Epidemiol. 2009 Jul-Aug;16(4):218-23.PMID: 19874142 [PubMed - in process]Related articles

    3.

    Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden.

    Bergström A, Maurel F, Le Pen C, Lamure E, Kent M, Bardoulat I, Berdeaux G.

    Clin Ophthalmol. 2009;3:471-81. Epub 2009 Aug 20.PMID: 19714225 [PubMed - in process]Related articlesFree article

    4.

    Cost of cataract surgery after implantation of three intraocular lenses.

    Boureau C, Lafuma A, Jeanbat V, Smith AF, Berdeaux G.

    Clin Ophthalmol. 2009;3:277-85. Epub 2009 Jun 2.PMID: 19668579 [PubMed - in process]Related articlesFree article

    5.

    Lifetime costs and effectiveness of ReSTOR compared with a monofocal IOL and Array-SA40 in the Netherlands.

    De Vries NE, Laurendeau C, Lafuma A, Berdeaux G, Nuijts RM.

    Eye (Lond). 2009 Jul 3. [Epub ahead of print]PMID: 19575029 [PubMed - as supplied by publisher]Related articles

    6.

    Incidence of Nd:YAG laser capsulotomies after cataract surgery: comparison of 3 square-edged lenses of different composition.

    Boureau C, Lafuma A, Jeanbat V, Berdeaux G, Smith AF.

    Can J Ophthalmol. 2009 Apr;44(2):165-70.PMID: 19491950 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Modelling the lifetime economic consequences of glaucoma in France.

    Philippe Nordmann J, Lafuma A, Berdeaux G.

    J Med Econ. 2009;12(1):9-16.PMID: 19450060 [PubMed - in process]Related articles

    8.

    Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK general practitioner research database.

    De Natale R, Lafuma A, Berdeaux G.

    Clin Drug Investig. 2009;29(2):111-20. doi: 10.2165/0044011-200929020-00005.PMID: 19133706 [PubMed - indexed for MEDLINE]Related articles

    9.

    Postcataract acute endophthalmitis in France: national prospective survey.

    Kodjikian L, Salvanet-Bouccara A, Grillon S, Forestier F, Seegmuller JL, Berdeaux G; French Collaborative Study Group on Endophthalmitis.

    J Cataract Refract Surg. 2009 Jan;35(1):89-97.PMID: 19101430 [PubMed - indexed for MEDLINE]Related articles

    10.

    Corrected and uncorrected near and distance vision with ReSTOR compared to monofocal intraocular lens implantation after cataract surgery: a pooled analysis.

    Cochener B, Arnould B, Viala M, Roborel de Climens A, Berdeaux G.

    Ophthalmologica. 2009;223(2):128-35. Epub 2008 Dec 18.PMID: 19092283 [PubMed - indexed for MEDLINE]Related articles

    11.

    Intraocular pressure control with latanoprost/timolol and travoprost/timolol fixed combinations : a retrospective, multicentre, cross-sectional study.

    Denis P, Lafuma A, Jeanbat V, Laurendeau C, Berdeaux G.

    Clin Drug Investig. 2008;28(12):767-76. doi: 10.2165/0044011-200828120-00004.PMID: 18991470 [PubMed - indexed for MEDLINE]Related articles

    12.

    Intermediate visual acuity without spectacles following bilateral ReSTOR implantation.

    Cuq C, Spera C, Laurendeau C, Lafuma A, Berdeaux G.

    Eur J Ophthalmol. 2008 Sep-Oct;18(5):733-8.PMID: 18850551 [PubMed - indexed for MEDLINE]Related articles

    13.

    A European survey of patient satisfaction with spectacles after cataract surgery and the associated costs in four European countries (france, Germany, Spain, and Italy).

    Cuq C, Lafuma A, Jeanbat V, Berdeaux G.

    Ophthalmic Epidemiol. 2008 Jul-Aug;15(4):234-41.PMID: 18780256 [PubMed - indexed for MEDLINE]Related articles

    14.

    Modelling lifetime cost consequences of ReSTOR for presbyopia in four European countries.

    Lafuma A, Berdeaux G.

    Eye (Lond). 2009 May;23(5):1072-80. Epub 2008 Jul 18.PMID: 18636081 [PubMed - in process]Related articles

    15.

    Modelling lifetime cost consequences of ReSTOR in cataract surgery in four European countries.

    Lafuma A, Berdeaux G.

    BMC Ophthalmol. 2008 Jul 15;8:12.PMID: 18627594 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy.

    Bandello F, Augustin A, Sahel JA, Benhaddi H, Negrini C, Hieke K, Berdeaux GH; MICMAC (MICro-economics of MACular degeneration) Study Group.

    Drugs Aging. 2008;25(3):255-68.PMID: 18331076 [PubMed - indexed for MEDLINE]Related articles

    19.

    Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France.

    Payet S, Denis P, Berdeaux G, Launois R.

    Clin Drug Investig. 2008;28(3):183-98.PMID: 18266403 [PubMed - indexed for MEDLINE]Related articles

    20.

    Patient-reported benefit of ReSTOR multi-focal intraocular lenses after cataract surgery: results of principal component analysis on clinical trial data.

    Berdeaux G, Viala M, Roborel de Climens A, Arnould B.

    Health Qual Life Outcomes. 2008 Jan 24;6:10.PMID: 18218068 [PubMed - indexed for MEDLINE]Related articlesFree article

    21.

    Treatment carryover impacts on effectiveness of intraocular pressure lowering agents, estimated by a discrete event simulation model.

    Denis P, Le Pen C, Umuhire D, Berdeaux G.

    Eur J Ophthalmol. 2008 Jan-Feb;18(1):44-51.PMID: 18203084 [PubMed - indexed for MEDLINE]Related articles

    24.

    Use of a Bayesian network to predict the nighttime intraocular pressure peak from daytime measurements.

    Nordmann JP, Berdeaux G.

    Clin Ther. 2007 Aug;29(8):1751-60; discussion 1750.PMID: 17919556 [PubMed - indexed for MEDLINE]Related articles

    25.

    Development of the conceptual framework for the Eye-Drop Satisfaction Questionnaire (EDSQ) in glaucoma using a qualitative study.

    Nordmann JP, Denis P, Vigneux M, Trudeau E, Guillemin I, Berdeaux G.

    BMC Health Serv Res. 2007 Aug 6;7:124.PMID: 17683594 [PubMed - indexed for MEDLINE]Related articlesFree article

    26.

    Health-related quality of life and utility in patients with age-related macular degeneration.

    Sahel JA, Bandello F, Augustin A, Maurel F, Negrini C, Berdeaux GH; MICMAC Study Group.

    Arch Ophthalmol. 2007 Jul;125(7):945-51.PMID: 17620576 [PubMed - indexed for MEDLINE]Related articlesFree article

    27.

    Estimating the Long-Term Visual Field Consequences of Average Daily Intraocular Pressure and Variance : A Clinical Trial Comparing Timolol, Latanoprost and Travoprost.

    Nordmann JP, Lepen C, Lilliu H, Berdeaux G.

    Clin Drug Investig. 2003;23(7):431-438.PMID: 17535054 [PubMed - as supplied by publisher]Related articles

    28.

    Medical Outcomes of Glaucoma Therapy from a Nationwide Representative Survey.

    Denis P, Lafuma A, Berdeaux G.

    Clin Drug Investig. 2004;24(6):343-352.PMID: 17516721 [PubMed - as supplied by publisher]Related articles

    29.

    Self-reported visual impairment and mortality: a French nationwide perspective.

    Berdeaux G, Brézin AP, Fagnani F, Lafuma A, Mesbah M.

    Ophthalmic Epidemiol. 2007 Mar-Apr;14(2):80-7.PMID: 17464855 [PubMed - indexed for MEDLINE]Related articles

    30.

    Anxiety and depression prevalence rates in age-related macular degeneration.

    Augustin A, Sahel JA, Bandello F, Dardennes R, Maurel F, Negrini C, Hieke K, Berdeaux G.

    Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1498-503.PMID: 17389477 [PubMed - indexed for MEDLINE]Related articlesFree article

    31.

    A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.

    Denis P, Lafuma A, Khoshnood B, Mimaud V, Berdeaux G.

    Curr Med Res Opin. 2007 Mar;23(3):601-8. Review.PMID: 17355741 [PubMed - indexed for MEDLINE]Related articles

    32.

    Comparison of diurnal intraocular pressure control by latanoprost versus travoprost : results of an observational survey.

    Denis P, Launois R, Devaux M, Berdeaux G.

    Clin Drug Investig. 2006;26(12):703-14.PMID: 17274677 [PubMed - indexed for MEDLINE]Related articles

    33.

    Quality of life and health economic assessments of age-related macular degeneration.

    Covert D, Berdeaux G, Mitchell J, Bradley C, Barnes R.

    Surv Ophthalmol. 2007 Jan;52 Suppl 1:S20-5. Review.PMID: 17240252 [PubMed - indexed for MEDLINE]Related articles

    34.

    Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity.

    Bandello F, Lafuma A, Berdeaux G.

    Invest Ophthalmol Vis Sci. 2007 Jan;48(1):96-103.PMID: 17197522 [PubMed - indexed for MEDLINE]Related articlesFree article

    35.

    Estimating the yearly number of eyes with treatable neovascular age-related macular degeneration using a direct standardization method and a markov model.

    Korobelnik JF, Moore N, Blin P, Dharmani C, Berdeaux G.

    Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4270-6.PMID: 17003415 [PubMed - indexed for MEDLINE]Related articlesFree article

    36.

    Nonmedical economic consequences attributable to visual impairment: a nation-wide approach in France.

    Lafuma A, Brezin A, Fagnani F, Mimaud V, Mesbah M, Berdeaux G.

    Eur J Health Econ. 2006 Sep;7(3):158-64.PMID: 16850334 [PubMed - indexed for MEDLINE]Related articles

    37.

    Prevalence of visual impairment in relation to the number of ophthalmologists in a given area: a nationwide approach.

    Lafuma AJ, Brézin AP, Fagnani FL, Mesbah M, Berdeaux GH.

    Health Qual Life Outcomes. 2006 Jun 6;4:34.PMID: 16756661 [PubMed - indexed for MEDLINE]Related articlesFree article

    38.

    Economic assessment of a maintenance treatment strategy in prevention of recurrent depressive disorder.

    Dardennes RM, Lafuma A, Fagnani F, Pribil C, Bisserbe JC, Berdeaux G.

    Value Health. 2000 Jan-Feb;3(1):40-7.PMID: 16464180 [PubMed]Related articles

    39.

    Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.

    Lafuma A, Brézin A, Lopatriello S, Hieke K, Hutchinson J, Mimaud V, Berdeaux G.

    Pharmacoeconomics. 2006;24(2):193-205.PMID: 16460138 [PubMed - indexed for MEDLINE]Related articles

    40.

    Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.

    Péchevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G, Ziegler M; Trial Study Group.

    Eur J Neurol. 2005 Dec;12(12):956-63.PMID: 16324089 [PubMed - indexed for MEDLINE]Related articles

    41.

    Clinical outcomes of glaucoma treatments over a patient lifetime: a Markov model.

    Nordmann JP, Lafuma A, Deschaseaux C, Berdeaux G.

    J Glaucoma. 2005 Dec;14(6):463-9.PMID: 16276278 [PubMed - indexed for MEDLINE]Related articles

    42.

    Cost-effectiveness analysis of PMMA, silicone, or acrylic intra-ocular lenses in cataract surgery in four European countries.

    Smith AF, Lafuma A, Berdeaux G, Berto P, Brueggenjuergen B, Magaz S, Auffarth GK, Brezin A, Caporossi A, Mendicute J.

    Ophthalmic Epidemiol. 2005 Oct;12(5):343-51.PMID: 16272054 [PubMed - indexed for MEDLINE]Related articles

    43.

    Scoring of visual field measured through Humphrey perimetry: principal component varimax rotation followed by validated cluster analysis.

    Nordmann JP, Mesbah M, Berdeaux G.

    Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3169-76.PMID: 16123416 [PubMed - indexed for MEDLINE]Related articlesFree article

    44.

    Prevalence and burden of self-reported blindness, low vision, and visual impairment in the French community: a nationwide survey.

    Brézin AP, Lafuma A, Fagnani F, Mesbah M, Berdeaux G.

    Arch Ophthalmol. 2005 Aug;123(8):1117-24.PMID: 16087847 [PubMed - indexed for MEDLINE]Related articles

    45.

    Prevalence and burden of self-reported blindness and low vision for individuals living in institutions: a nationwide survey.

    Brézin AP, Lafuma A, Fagnani F, Mesbah M, Berdeaux G.

    Health Qual Life Outcomes. 2005 Apr 25;3:27.PMID: 15847703 [PubMed - indexed for MEDLINE]Related articlesFree article

    46.

    The economic burden of glaucoma and ocular hypertension: implications for patient management: a review.

    Rouland JF, Berdeaux G, Lafuma A.

    Drugs Aging. 2005;22(4):315-21. Review.PMID: 15839720 [PubMed - indexed for MEDLINE]Related articles

    47.

    Vision-related quality of life in patients suffering from age-related macular degeneration.

    Berdeaux GH, Nordmann JP, Colin E, Arnould B.

    Am J Ophthalmol. 2005 Feb;139(2):271-9.PMID: 15733988 [PubMed - indexed for MEDLINE]Related articles

    48.

    The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom.

    Bonastre J, Le Pen C, Anderson P, Ganz A, Berto P, Berdeaux G.

    Eur J Health Econ. 2002;3(2):94-102.PMID: 15609135 [PubMed]Related articles

    49.

    Comparison of Nd : YAG capsulotomy rates following phacoemulsification with implantation of PMMA, silicone, or acrylic intra-ocular lenses in four European countries.

    Auffarth GU, Brezin A, Caporossi A, Lafuma A, Mendicute J, Berdeaux G, Smith AF; European PCO Study Group.

    Ophthalmic Epidemiol. 2004 Oct;11(4):319-29.PMID: 15512993 [PubMed - indexed for MEDLINE]Related articles

    50.

    Adverse clinical consequences of neodymium:YAG laser treatment of posterior capsule opacification.

    Billotte C, Berdeaux G.

    J Cataract Refract Surg. 2004 Oct;30(10):2064-71.PMID: 15474815 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data

    Search details

    » See more...